Health Headlines: Lancet Rejects Inquiry, CBD Law Updates, and Device Coverage Accelerations
The Lancet medical journal will not provide evidence for a U.S. Senate COVID-19 inquiry. President Trump urges Congress to update laws for CBD product access. U.S. health regulators plan to expedite Medicare device coverage. The UK investigates data sales on Alibaba. Edwards Lifesciences and Sanofi report earnings, and the FDA fast-tracks psychedelic drug approvals.
The esteemed Lancet medical journal has declined a U.S. Senate request for evidence regarding the COVID-19 origins investigation, according to editor-in-chief Richard Horton. Horton confirmed their decision at a Reuters Pharma event, saying the journal will not participate in the inquiry.
In a recent Truth Social post, President Donald Trump requested Congress to revise current laws to ensure full-spectrum cannabidiol (CBD) product accessibility for Americans. This move reflects ongoing efforts to improve legislative support for CBD usage.
Meanwhile, U.S. health regulators unveiled a new initiative to accelerate Medicare coverage for medical devices. This strategy aims to reduce the reimbursement wait times drastically, encouraging innovation within the medical device industry, which has long faced hurdles due to prolonged approval processes.
(With inputs from agencies.)
- READ MORE ON:
- health
- COVID-19
- Lancet
- Senate
- CBD
- Trump
- Medicare
- medical devices
- FDA
- psychedelic drugs
ALSO READ
Trump says he's called off Iran strike planned for Tuesday at request of Gulf allies to allow for 'serious negotiations,' reports AP.
High-Stakes Dismissal: Trump Administration Drops Charges Against Billionaire Adani
Trump's $1.76 Billion Fund: A Political Maneuver or Justice?
TrumpRx Expansion: A New Era in Prescription Drugs
Trump's $1.8 Billion Settlement Fund: Anti-Weaponization or Political Maneuver?
Google News